Ruscogenin Ameliorates Experimental Nonalcoholic Steatohepatitis via Suppressing Lipogenesis and Inflammatory Pathway

Table 1

Effects of ruscogenin on body weight, liver and visceral fat weight, and feeding behaviors of hamsters.

	RCD-fed	HFD-fed
	Vehicle	Vehicle	Ruscogenin (mg/kg/day)
			0.3	1.0	3.0
Final body weight (BW) (g)	127.1±9.1^d	164.3±7.1^b	158.4±8.1^b	153.9±6.3^b	147.3 ± 7.3^a,c
Epididymal WAT (g/100 g BW)	1.6±0.3^d	2.5±0.3^b	2.1±0.4^b	1.9±0.2^d	1.8±0.3^d
Perirenal WAT (g/100 g BW)	0.8±0.2^c	1.2±0.2^a	1.1±0.3	1.1±0.2	0.9±0.2
Liver weight (g/100 g BW)	4.8±0.3^c	5.7±0.3^a	5.5±0.3^a	5.2±0.3	5.1±0.3
Food intake (g/day)	9.9±1.3	11.0±1.3	10.7±1.8	10.9±1.4	9.8±1.5
Water intake (mL/day)	12.6±4.4	13.2±6.2	13.0±4.5	12.6±5.9	13.1±4.3

The vehicle (distilled water) used to prepare the tested medication solution was given at the same volume. Values (mean ± SEM) were obtained from each group of 8 animals after 8 weeks of the experimental period. ^a𝑃<0.05 and ^b𝑃<0.01 compared to the values of vehicle-treated RCD-fed hamsters in each group, respectively. ^c𝑃<0.05 and ^d𝑃<0.01 compared to the values of vehicle-treated HFD-fed hamsters in each group, respectively.